BioLineRx (BLRX) Revenue (2024 - 2025)
BioLineRx (BLRX) posted Revenue of $194000.0 for Q4 2025, down 54.57% on a QoQ basis from $427000.0 in Q3 2025, and down 98.35% year-over-year from $11.7 million in Q4 2024.
BioLineRx (BLRX) has 2 years of Revenue data on file, last reported at $194000.0 in Q4 2025.
- In Q4 2025, Revenue fell 98.35% year-over-year to $194000.0; the TTM figure through Dec 2025 stood at $1.2 million (down 95.92% YoY), while the FY2025 annual figure was $1.2 million, down 95.92% from the prior year.
- Revenue fell to $194000.0 in Q4 2025, from $427000.0 in the prior quarter.
- Across five years, Revenue topped out at $11.7 million in Q4 2024 and bottomed at $194000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | 194,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 194,000.00 |
| Sep 30, 2025 | 427,000.00 |
| Jun 30, 2025 | 304,000.00 |
| Mar 31, 2025 | 255,000.00 |
| Dec 31, 2024 | 11.75 Mn |
| Sep 30, 2024 | 4.94 Mn |
| Jun 30, 2024 | 5.39 Mn |
| Mar 31, 2024 | 6.86 Mn |